UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors

CPT: pharmacometrics and systems pharmacology, 2017-01, Vol.6 (1), p.49-57

2017

Volltextzugriff (PDF)

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti–PD‐1 Antibody Pembrolizumab

CPT: pharmacometrics and systems pharmacology, 2017-01, Vol.6 (1), p.11-20

2017

Volltextzugriff (PDF)

Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial

CPT: pharmacometrics and systems pharmacology, 2017-01, Vol.6 (1), p.21-28

2017

Volltextzugriff (PDF)

Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation

The AAPS journal, 2005-10, Vol.7 (3), p.E544-E559

2005

Volltextzugriff (PDF)

Considerations in the design and development of transport inhibitors as adjuncts to drug therapy

Advanced drug delivery reviews, 2003-01, Vol.55 (1), p.133-150

2003

Volltextzugriff (PDF)

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma

CPT: pharmacometrics and systems pharmacology, 2017-01, Vol.6 (1), p.29-39

2017

Volltextzugriff (PDF)

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice

European journal of cancer (1990), 2008-01, Vol.44 (1), p.142-150

2008

Volltextzugriff (PDF)

Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma

CPT: pharmacometrics and systems pharmacology, 2017-01, Vol.6 (1), p.5-7

2017

Volltextzugriff (PDF)

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

Clinical cancer research, 2004-05, Vol.10 (10), p.3265-3272

2004

Volltextzugriff (PDF)

Using Model-Based “Learn and Confirm” to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial: Modeling of the PK/PD of Pembro in KEYNOTE-001

CPT: pharmacometrics and systems pharmacology, 2017-01, Vol.6 (1), p.21-28

2017

Volltextzugriff (PDF)

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab: Translational Pharmacokinetic/Pharmacodynamic Modeling

CPT: pharmacometrics and systems pharmacology, 2017-01, Vol.6 (1), p.11-20

2017

Volltextzugriff (PDF)

Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma: Modeling and Simulation of Pembrolizumab

CPT: pharmacometrics and systems pharmacology, 2017-01, Vol.6 (1), p.5-7

2017

Volltextzugriff (PDF)

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors: Pharmacokinetics of Pembro in Solid Tumors

CPT: pharmacometrics and systems pharmacology, 2017-01, Vol.6 (1), p.49-57

2017

Volltextzugriff (PDF)

Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies

Clinical cancer research, 2004-11, Vol.10 (21), p.7220-7228

2004

Volltextzugriff (PDF)

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar.3HCl Trihydrochloride (LY335979), Administered Orally in Combination with Doxorubicin in Patients with Advanced Malignancies

Clinical cancer research, 2002-12, Vol.8 (12), p.3710-3717

2002

Volltextzugriff (PDF)

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma: Tumor Modeling in Pembrolizumab-Treated Melanoma

CPT: pharmacometrics and systems pharmacology, 2017-01, Vol.6 (1), p.29-39

2017

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of LY293111, an Orally Bioavailable LTB4 Receptor Antagonist, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2005-08, Vol.23 (23), p.5365

2005

Volltextzugriff (PDF)

Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours

Cancer chemotherapy and pharmacology, 2005-08, Vol.56 (2), p.154-160

2005

Volltextzugriff (PDF)

Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979)

Cancer chemotherapy and pharmacology, 2004-07, Vol.54 (1), p.39-48

2004

Volltextzugriff (PDF)

A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)

Cancer chemotherapy and pharmacology, 2003-02, Vol.51 (2), p.107-118

2003

Volltextzugriff (PDF)

A population pharmacokinetic model for paclitaxel in the presence of a novel P‐gp modulator, Zosuquidar Trihydrochloride (LY335979)

British journal of clinical pharmacology, 2003-07, Vol.56 (1), p.46-56

2003

Volltextzugriff (PDF)

Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements

Clinical pharmacology and therapeutics, 1998-12, Vol.64 (6), p.622-635

1998

Volltextzugriff (PDF)

Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: Application to moxonidine

Clinical pharmacology and therapeutics, 2000-07, Vol.68 (1), p.18-27

2000

Volltextzugriff (PDF)

Population pharmacokinetics of ondansetron: a covariate analysis

British journal of clinical pharmacology, 1998-08, Vol.46 (2), p.117-125

1998

Volltextzugriff (PDF)

Drug Transporters and Their Role in Tissue Distribution

Annual Reports in Medicinal Chemistry, 2004, Vol.39, p.277-291

2004

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)
Buchkapitel
(1)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti–PD‐1 Antibody Pembrolizumab

Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial

Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation

Considerations in the design and development of transport inhibitors as adjuncts to drug therapy

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice

Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

Using Model-Based “Learn and Confirm” to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial: Modeling of the PK/PD of Pembro in KEYNOTE-001

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab: Translational Pharmacokinetic/Pharmacodynamic Modeling

Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma: Modeling and Simulation of Pembrolizumab

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors: Pharmacokinetics of Pembro in Solid Tumors

Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar.3HCl Trihydrochloride (LY335979), Administered Orally in Combination with Doxorubicin in Patients with Advanced Malignancies

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma: Tumor Modeling in Pembrolizumab-Treated Melanoma

Phase I and Pharmacokinetic Study of LY293111, an Orally Bioavailable LTB4 Receptor Antagonist, in Patients With Advanced Solid Tumors

Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours

Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979)

A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)

A population pharmacokinetic model for paclitaxel in the presence of a novel P‐gp modulator, Zosuquidar Trihydrochloride (LY335979)

Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements

Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: Application to moxonidine

Population pharmacokinetics of ondansetron: a covariate analysis

Drug Transporters and Their Role in Tissue Distribution

Suchergebnisse filtern